BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang F, Gao S, Wu M, Zhao D, Sun H, Yav S, Chen Y, Zhang Z, Yang M, Dong Y, Wang J, Wang X, Yan Z, Liu L. The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE. BMC Gastroenterol 2023;23:80. [PMID: 36944920 DOI: 10.1186/s12876-023-02719-1] [Reference Citation Analysis]
2 Settar A, Khaldoun H, Tarzaali D, Djennane N, Makhlouf C, Selmani I, Yasmine O, Amel K. Lambda cyhalothrin and chlorantraniliprole caused biochemical, histological, and immunohistochemical alterations in male rabbit liver: Ameliorative effect of vitamins A, D, E, C mixture. Toxicology 2023;487:153464. [PMID: 36813254 DOI: 10.1016/j.tox.2023.153464] [Reference Citation Analysis]
3 Yang L, Wang J, Yao L, Chen C, Pan J, Peng L, Chen F. Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma. Heliyon 2023. [DOI: 10.1016/j.heliyon.2023.e14460] [Reference Citation Analysis]
4 Pan A, Truong TN, Su YH, Dao DY. Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings. Diagnostics (Basel) 2023;13. [PMID: 36832164 DOI: 10.3390/diagnostics13040676] [Reference Citation Analysis]
5 Li J, Li C, Zhu G, Yang J, Zhang Y, Yu Z, Xia J. A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making. Ann Transl Med 2023;11:68. [PMID: 36819596 DOI: 10.21037/atm-22-6513] [Reference Citation Analysis]
6 Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol 2022;12:1091088. [PMID: 36727075 DOI: 10.3389/fonc.2022.1091088] [Reference Citation Analysis]
7 Liang L, Wang X, Huang S, Chen Y, Zhang P, Li L, Cui Y. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. Front Immunol 2023;14:1046771. [PMID: 36936932 DOI: 10.3389/fimmu.2023.1046771] [Reference Citation Analysis]
8 Zhang Y, Xie Y, Huang X, Zhang L, Shu K. Screening of Hub Genes in Hepatocellular Carcinoma Based on Network Analysis and Machine Learning. Comput Math Methods Med 2022;2022:7300788. [PMID: 36479313 DOI: 10.1155/2022/7300788] [Reference Citation Analysis]
9 Necula L, Matei L, Dragu D, Pitica I, Neagu A, Bleotu C, Diaconu CC, Chivu-economescu M. Collagen Family as Promising Biomarkers and Therapeutic Targets in Cancer. IJMS 2022;23:12415. [DOI: 10.3390/ijms232012415] [Reference Citation Analysis]
10 Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol 2022;16:903-11. [PMID: 35999514 DOI: 10.1080/17474124.2022.2117156] [Reference Citation Analysis]
11 Khan A, Zhang X. Function of the Long Noncoding RNAs in Hepatocellular Carcinoma: Classification, Molecular Mechanisms, and Significant Therapeutic Potentials. Bioengineering 2022;9:406. [DOI: 10.3390/bioengineering9080406] [Reference Citation Analysis]
12 Zhang G, Yun Y, Lin C, Li H. Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation. Evid Based Complement Alternat Med 2022;2022:5132135. [PMID: 35911145 DOI: 10.1155/2022/5132135] [Reference Citation Analysis]
13 Cao X, Shao Y, Meng P, Cao Z, Yan G, Yao J, Zhou X, Liu C, Zhang L, Shu H, Lu H. Nascent Proteome and Glycoproteome Reveal the Inhibition Role of ALG1 in Hepatocellular Carcinoma Cell Migration. Phenomics 2022;2:230-41. [PMID: 36939752 DOI: 10.1007/s43657-022-00050-5] [Reference Citation Analysis]
14 Yan Q, Sun Y, An R, Liu F, Fang Q, Wang Z, Xu T, Chen L, Du J. Application and progress of the detection technologies in hepatocellular carcinoma. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.04.003] [Reference Citation Analysis]
15 Melis M, Tang X, Trasino SE, Gudas LJ. Retinoids in the Pathogenesis and Treatment of Liver Diseases. Nutrients 2022;14:1456. [DOI: 10.3390/nu14071456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]